March 2025
1. SERPA F, Perera S, Cruz D, Figueroa JF, et al
   Cardiovascular Health, Lifestyle Factors, and Social Determinants Among Hispanic or Latino Adults in the United States.
   Am Heart J. 2025 Mar 9:S0002-8703(25)00070-5. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   February 2025
2. CHATUR S, Seth M, Casey M, Thompson M, et al
   Reminders EMbedded IN PCI Reports to Optimize Discharge Diabetes Mellitus Care (REMIND-DM): Rationale, Design, and Baseline Characteristics.
   Am Heart J. 2025 Feb 21:S0002-8703(25)00019-5. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   
3. HAFF N, Horn DM, Bhatkhande G, Sung M, et al
   Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
   Am Heart J. 2025 Feb 20:S0002-8703(25)00038-9. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   
4. TIAN Y, Wang X, Hu Z, Yu X, et al
   Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study).
   Am Heart J. 2025 Feb 13:S0002-8703(25)00035-3. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   
5. GAO XF, Kan J, Wu HY, Chen J, et al
   Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
   Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   January 2025
6. EBRAHIMI M, Fonarow GC
   Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
   Am Heart J. 2025 Jan 23:S0002-8703(25)00008-0. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   
7. BLOOD AJ, Chang LS, Colling C, Stern G, et al
   Type 2 Diabetes Disease and Management Patterns Across a Large, Diverse Healthcare System: Issues and Opportunities for Guideline-Directed Therapies.
   Am Heart J. 2025 Jan 6:S0002-8703(25)00003-1. doi: 10.1016/j.ahj.2025.
   

   >> Share

   
   December 2024
8. NELSON AJ, Kaltenbach LA, McGuire DK, Levya M, et al
   Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
   Am Heart J. 2024 Dec 21:S0002-8703(24)00336-3. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   
9. HASSAN S, Chang LS, Gabovitch D, Chasse J, et al
   Enrollment strategies in the era of digital revolution: Experience from a remote health management program.
   Am Heart J. 2024;278:181-185.
   

   >> Share

   
   November 2024
10. NAVAS-ACIEN A, Mark DB, Anstrom K, Lamas GA, et al
    Response to Tomoyuki Kawada: Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:143-144.
    

    >> Share

    
    
11. KAWADA T
    Blood and urine metal levels in patients with diabetes and cardiovascular disease.
    Am Heart J. 2024;277:142.
    

    >> Share

    
    September 2024
12. KERCHEVAL JB, Narcisse DI, Nguyen M, Rao SV, et al
    Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study.
    Am Heart J. 2024;275:183-190.
    

    >> Share

    
    August 2024
13. HAMID H, Bagheri M, Benzing T, Krishnan S, et al
    Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression: The (T-PLAQUE) randomized-controlled trial design: tirzepatide and plaque.
    Am Heart J. 2024 Aug 24:S0002-8703(24)00218-7. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    May 2024
14. COMMODORE-MENSAH Y, Chen Y, Ogungbe O, Liu X, et al
    Design and Rationale of the Cardiometabolic Health Program Linked with Community Health Workers and Mobile Health Telemonitoring to Reduce Health DisparitieS (LINKED-HEARTS) Program.
    Am Heart J. 2024 May 15:S0002-8703(24)00123-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
15. JANUZZI JL JR, Liu Y, Sattar N, Yavin Y, et al
    Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
    Am Heart J. 2024;271:38-47.
    

    >> Share

    
    April 2024
16. GAGNON LR, Hazra D, Perera K, Wang K, et al
    Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
    Am Heart J. 2024 Apr 24:S0002-8703(24)00094-2. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
17. HEERSPINK HJ, Provenzano M, Vart P, Jongs N, et al
    Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
    Am Heart J. 2024;270:125-135.
    

    >> Share

    
    February 2024
18. RAO VN, Sharma A, Stebbins A, Buse JB, et al
    Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00040-1. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
19. ANDERSEN CF, Larsen JH, Jensen J, Omar M, et al
    Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
    Am Heart J. 2024 Feb 14:S0002-8703(24)00032-2. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share